Trial Profile
Non-interventional Study Describing Patients' Perception on Anticoagulant Treatment and Treatment Convenience When Treated With Pradaxa or Vitamin K Antagonist for Stroke Prophylaxis in Atrial Fibrillation
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Dabigatran etexilate (Primary) ; Vitamin K antagonists
- Indications Stroke
- Focus Therapeutic Use
- Sponsors Boehringer Ingelheim
- 21 Feb 2017 Status changed from active, no longer recruiting to completed.
- 25 Jul 2016 Status changed from recruiting to active, no longer recruiting.
- 20 May 2016 Planned number of patients changed from 3000 to 1605.